Lung cancer and rheumatoid arthritis. An interdisciplinary challenge

Zeitschrift für Rheumatologie
A Rubbert-RothC Witt

Abstract

Lung cancer is a frequently occurring disease, particularly in the elderly; however, within the last 10 years the pharmaceutical treatment of lung cancer has been significantly improved. Due to a better understanding of the pathophysiological events and the identification of molecular subgroups of lung tumors, new therapeutic drugs have been developed that significantly prolong survival of patients with the respective molecular pattern. In particular immunotherapeutic agents, such as programmed death-ligand 1 (PD-L1) and programmed death 1 (PD1) antibodies have shown promising clinical results in a subgroup of lung cancer patients. Due to the high incidence of both lung cancer and rheumatic diseases they often occur together, which necessitates an interdisciplinary management. The success of improved therapy of lung cancer has led to a greater focus on the treatment of comorbidities; however, interventions into the immune system by immune checkpoint inhibitors can lead to new challenges when an autoimmune disease is simultaneously present. The possibility of an effective screening for lung cancer in the future also presents the prospect of an improvement in mortality, which raises the question of the optimal monitoring of patie...Continue Reading

References

Jan 5, 2000·American Journal of Respiratory and Critical Care Medicine·R HubbardJ Britton
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claire SiemesBruno H Ch Stricker
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Apr 25, 2008·Arthritis Research & Therapy·Allison L SmittenSamy Suissa
May 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre PignonUNKNOWN LACE Collaborative Group
Mar 23, 2010·Pneumologie·G GoeckenjanUNKNOWN Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin und die Deutsche Krebsgesellschaft
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Feb 1, 2011·The Lancet Oncology·William Pao, Nicolas Girard
Jul 1, 2011·The New England Journal of Medicine·UNKNOWN National Lung Screening Trial Research TeamJoRean D Sicks
Jan 31, 2012·The Lancet Oncology·Rafael RosellUNKNOWN Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia T
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Dec 15, 2012·Rheumatology·Louise K MercerUNKNOWN British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium
Apr 6, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·M BosJ Wolf
Apr 17, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Reinhard BuettnerRoman K Thomas
Dec 18, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Liang ShiZhe Liu
Oct 28, 2014·Expert Opinion on Drug Safety·Mauricio BurottoGeraldine O'Sullivan Coyne
Nov 5, 2014·American Journal of Respiratory and Critical Care Medicine·Lynn T TanoueGerard A Silvestri
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
May 20, 2015·Journal of Thoracic Disease·Michael W MarcusJohn K Field
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Aug 16, 2015·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Jody C ChuangHeather A Wakelee
Aug 16, 2015·The Journal of Rheumatology·Ronald F van VollenhovenPatricia B Lehane

❮ Previous
Next ❯

Citations

Dec 15, 2020·JAMA Network Open·Saya JacobVictoria Villaflor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Related Papers

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
Hidenobu IshiiTomoaki Hoshino
Expert Opinion on Emerging Drugs
Francesca CasaluceCesare Gridelli
© 2021 Meta ULC. All rights reserved